CRESCENT BIOPHARMA, INC. Investment Income, Nonoperating
CRESCENT BIOPHARMA, INC. (CBIO) reported Investment Income, Nonoperating of $1.53 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. investment income, nonoperating for the quarter ending 2026-06-30 was $1.53M, a 387.86% increase year-over-year.
- CRESCENT BIOPHARMA, INC. investment income, nonoperating for the quarter ending 2026-03-31 was $1.45M, a 669.15% increase year-over-year.
- CRESCENT BIOPHARMA, INC. investment income, nonoperating for the quarter ending 2025-12-31 was $1.09M, a 522.16% increase year-over-year.
- CRESCENT BIOPHARMA, INC. investment income, nonoperating for the quarter ending 2025-09-30 was $1.28M.
- CRESCENT BIOPHARMA, INC. investment income, nonoperating for fiscal 2025 was $2.88M.
| Period end | Investment Income, Nonoperating 0 month | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month | Investment Income, Nonoperating 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.53M 10-Q · filed 2026-07-30 | $2.97M 10-Q · filed 2026-07-30 | $4.07M derived: sum of 3 quarters · filed 2026-07-30 | $5.35M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $1.45M 10-Q · filed 2026-04-29 | $2.54M derived: sum of 2 quarters · filed 2026-04-29 | $3.82M derived: sum of 3 quarters · filed 2026-04-29 | $4.13M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.37M derived: sum of 2 quarters · filed 2026-02-26 | $2.69M derived: sum of 3 quarters · filed 2026-07-30 | $2.88M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.28M 10-Q · filed 2025-11-06 | $1.59M derived: sum of 2 quarters · filed 2026-07-30 | $1.78M 10-Q · filed 2025-11-06 | $1.96M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $313.00K 10-Q · filed 2026-07-30 | $502.00K 10-Q · filed 2026-07-30 | $677.00K derived: sum of 3 quarters · filed 2026-07-30 | ||
| 2025-03-31 | $188.00K 10-Q · filed 2026-04-29 | $364.00K derived: sum of 2 quarters · filed 2026-04-29 | |||
| 2024-12-31 | $176.00K 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |